In vitro/in vivo correlations for respiratory drug delivery

Clinical Research and Regulatory Affairs

Volumn 22, Issue 1, 2005, Pages 15-30

  Newman, Stephen P ^a   Pitcairn, Gary R ^a  

^a PHARMACEUTICAL PROFILES LTD   (United Kingdom)

Author keywords

In Vitro Testing; In Vivo Testing; Nasal Drug Delivery; Pulmonary Drug Delivery

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; BECLOMETASONE DIPROPIONATE; CROMOGLYCATE DISODIUM; FLUNISOLIDE; FLUTICASONE PROPIONATE; GLUCOCORTICOID; INSULIN; MOMETASONE FUROATE; NOSE SPRAY; SALBUTAMOL; ZANAMIVIR;

AEROSOL; ASTHMA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG RELEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHALER; LUNG; METERED DOSE INHALER; NEBULIZER; PARTICLE SIZE; PHARMACOKINETICS; POSITRON EMISSION TOMOGRAPHY; QUALITY CONTROL; REVIEW; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TECHNIQUE;

EID: 19944370488     PISSN: 10601333     EISSN: 15322521     Source Type: Journal    
DOI: 10.1081/CRP-54959     Document Type: Review

References (61)

1. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part 1: physiological factors affecting therapeutic effectiveness of aerosolised medications. Br J Clin Pharmacol 2003; 56:588-599.
2. Labiris NR, Dolovich MB. Pulmonary drug delivery. Part 2: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolised medications. Br J Clin Pharmacol 2003; 56:600-612.
3. Mygind N, Weeke B. Allergic and Vasomotor Rhinitis: Clinical Aspects. Copenhagen: Munksgaard, 1985.
4. Illum L. Nasal drug delivery-possibilities, problems and solutions. J Control Release 2003; 87:187-198.
5. Illum L. Is nose-to-brain transport of drugs in man a reality? J Pharm Pharmacol 2004; 56:3-17.
6. Taylor G, Gumbleton M. Aerosols for macromolecule delivery: design challenges and solutions. Am J Drug Delivery 2004; 2:143-210.
7. British Association for Lung Research. Determining equivalence of inhaled medications. Respir Med 1995; 89:253-261.
8. Adams WP, Singh GJP, Williams RL. Nasal inhalation aerosols and metered dose spray pumps: FDA bioequivalence issues. In: Respiratory Drug Delivery VI. Dalby RN, Byron PR, Farr SJ, eds. Buffalo Grove: Interpharm Press, 1998:219-225.
9. Newman SP, Hirst PH, Pitcairn GR, Rankin L. Radionuclide imaging techniques and their use for evaluating asthma drug deposition in the lungs. Adv Drug Deliv Rev 2003; 55:851-867.
10. Newman SP, Illum L. Radionuclide imaging studies in the assessment of nasal drug delivery in humans. Am J Drug Deliv 2004; 2:101-112.
11. Mobley C, Hochhaus G. Methods used to assess pulmonary deposition and absorption of drugs. Drug Discov Today 2001; 6:367-375.
12. Laube BL. Advances in treating systemic diseases with aerosolized medicine. In: Drug Delivery to the Lungs XII. Portishead: The Aerosol Society, 2001:7-14.
13. Brain JD, Blanchard JD. Mechanisms of particle deposition and clearance. In: Aerosols in Medicine: Principles, Diagnosis and Therapy. 2nd ed. Morén F, Dolovich MB, Newhouse MT, Newman SP, eds. Amsterdam: Elsevier, 1993:117-156.
14. USP Advisory Panel. Recommendations of the USP advisory panel on aerosols on the USP general chapters on aerosols and uniformity of dosage units. Pharm Forum 1994; 20:7477-7505.
15. Hindle M, Byron PR. Dose emissions from marketed dry powder inhalers. Int J Pharm 1995; 116:169-177.
16. Mitchell JP, Nagel MW. Cascade impactors for size characterization of aerosols from medical inhalers: their uses and limitations. J Aerosol Med 2003; 16:341-377.
17. Ganderton D, Byron P. Harmonising inhaler testing across the Pharmacopeias. In: Respiratory Drug Delivery V. Dalby RN, Byron PR, Farr SJ, eds. Buffalo Groe: Interpharm Press, 1996:283-292.
18. Hallworth GW. Particle size analysis of therapeutic aerosols. In: Aerosols in Medicine: Principles, Diagnosis and Therapy. 2nd ed. Morén F, Dolovich MB, Newhouse MT, Newman SP, eds. Elsevier: Amsterdam, 1993:351-374.
19. Marple VA, Roberts DL, Romay FJ, Miller NC, Truman KG, Van Oort M, Olsson B, Holroyd MJ, Mitchell JP, Hochrainer D. Next generation pharmaceutical impactor-a new impactor for pharmaceutical inhaler testing. Part I: design. J Aerosol Med 2003; 16:283-299.
20. Dennis JH, Pieron CA, Nerbrink O. Standards in assessing in vitro nebulizer performance. Eur Respir Rev 2000; 10:178-182.
21. Van Oort M, Truman K. What is a respirable dose? J Aerosol Med 1998; 11:S89-S96.
22. Clark AR. The use of laser diffraction for the evaluation of the aerosol clouds generated by medical nebulizers. Int J Pharm 1995; 115:69-78.
23. Mitchell JP, Nagel MW. Time-of-flight aerodynamic particle size analysers: their use and limitations for the evaluation of medical aerosols. J Aerosol Med 1999; 12:217-240.
24. Dolovich MB. Measuring total and regional lung deposition using inhaled radiotracers. J Aerosol Med 2001; 14:S35-S44.
25. Smaldone GC. Radionuclide scanning, respiratory physiology and pharmacokinetics. J Aerosol Med 2001; 14:135-137.
26. Berridge MS, Lee Z, Heald DL. Regional distribution and kinetics of inhaled pharmaceuticals. Curr Pharm Des 2000; 6:1631-1651.
27. Fleming JS, Conway JH. Three-dimensional imaging of aerosol deposition. J Aerosol Med 2001; 14:147-153.
28. Fleming JS. Measuring drug deposition by airway generation in humans. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, eds. River Grove: Davis Healthcare International, 2004:187-193.
29. Pitcairn GR, Kalirai CS, Joyson A, Newman SP, Fleming JS. Development of a standard method for quantifying regional lung deposition from SPECT and relating the data to airway anatomy. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, eds. River Grove: Davis Healthcare International, 2004:621-624.
30. Warren S, Taylor G. Quality control aspects of pharmaceutical gamma scintigraphy studies. Eur Pharm Contract March 2004:88-94.
31. Dolovich M, Hahmias C, Coates G. Unleashing the PET: 3D imaging of the lung. In: Respiratory Drug Delivery VII. Dalby RN, Byron PR, Farr SJ, Peart J, eds. Raleigh: Serentec Press, 2000:215-230.
32. Derendorf H, Hochhaus G, Möllman H. Evaluation of pulmonary absorption using pharmacokinetic methods. J Aerosol Med 2001; 14:S9-S17.
33. Hindle M, Chrystyn H. Determination of the relative bioavailability of salbutamol to the lung following inhalation. Br J Clin Pharmacol 1992; 34:311-315.
34. Newnham DM, McDevitt DG, Lipworth BJ. Comparison of the extrapulmonary beta-2 adrenoceptor responses and pharmacokinetics of salbutamol metered dose-inhaler and modified actuator device. Br J Clin Pharmacol 1993; 36:445-450.
35. Borgström L, Nilsson M. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm Res 1990; 7:1069-1070.
36. Newman SP, Steed K, Hooper G, Källén A, Borgström L. Comparison of gamma scintigraphy and a pharmacokinetic technique for assessing pulmonary deposition of terbutaline sulphate delivered by pressurised metered dose inhaler. Pharm Res 1995; 12:231-236.
37. Newman SP. How well do in vitro particle size measurements predict drug delivery in vivo? J Aerosol Med 1998; 11:S97-S104.
38. Farr SJ, Warren SJ, Lloyd P, Okikawa JK, Schuster JA, Rowe AM, Rubsamen RM, Taylor G. Comparison of in vitro and in vivo efficiencies of a novel unit-dose aerosol generator and a pressurized metered dose inhaler. Int J Pharm 2000; 198:63-70.
39. Ross DL, Gabbrio BJ. Advances in metered dose inhaler technology with the development of a chlorofluorocarbon-free drug delivery system. J Aerosol Med 1999; 12:151-160.
40. Richards J, Hirst PH, Pitcairn GR, Mahashabde S, Abramowitz W, Nolting A, Newman SP. Deposition and pharmacokinetics of flunisolide delivered from pressurized inhalers containing non-CFC and CFC propellants. J Aerosol Med 2001; 14:197-208.
41. Pickering H, Pitcairn GR, Hirst PH, Bacon RE, Newman SP, Affrime MB, Marino M. Regional lung deposition of a technetium 99m-labeled formulation of mometasone furoate administered by hydrofluoroalkane 227 metered dose inhaler. Clin Ther 2000; 22:1483-1493.
42. Finlay WH, Zhang Y, Grgic B, Heenan A, Burnell P, Matilda EA, Plooard A, Lange CF. Solving a major in vitro-in vivo correlation problem: impactor induction ports. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, eds. River Grove: Davis Healthcare International, 2004:203-210.
43. Olsson B, Borgström L, Asking L, Bondesson E. Effect of inlet throat on the correlation between measured fine particle dose and lung deposition. In: Respiratory Drug Delivery V. Dalby RN, Byron PR, Farr SJ, eds. Buffalo Grove: Interpharm Press, 1996:273-281.
44. Pitcairn GR, Lim J, Hollingworth A, Newman SP. Scintigraphic assessment of drug delivery from the Ultrahaler dry powder inhaler. J Aerosol Med 1997; 10:295-306.
45. Brindley A, Reavill KJ, Sumby BS, Smith IJ. The in-vitro characterization of inhalation devices using the electronic lung. In: Respiratory Drug Delivery IV. Dalby RN, Byron PR, Farr SJ, eds. Buffalo Grove: Interpharm Press, 1994:143-151.
46. Borgstrom L, Bengtsson T, Derom E, Pauwels R. Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and with a dry powder inhaler, Turbuhaler. Int J Pharm 2000; 193:227-230.
47. Silkstone VL, Dennis JH, Pieron CA, Chrystyn H. An investigation of in vitro/in vivo correlations for salbutamol nebulized by eight systems. J Aerosol Med 2002; 15:251-259.
48. US FDA. Draft guidance for industry: bioavailability and bioequivalence studies for nasal aerosols and nasal sprays for local action. US Food and Drug Administration: Washington, 2003.
49. Pharmaceutical Previews, Chapter 601. Aerosols, metered dose inhalers and dry powder inhalers. Pharm Forum 1996; 22:3065-3095.
50. Newman SP, Pitcairn GR, Dalby RN. Drug delivery to the nasal cavity: in vitro and in vivo assessment. Crit Rev Ther Drug Deliv Syst 2004; 21:21-66.
51. Su G, Farina D, Langridge J, Riehle K, Somaruja S, Suman J. Effect of actuation parameters on spray weight, droplet size, spray pattern and plume geometry for viscous nasal spray formulations. In: Drug Delivery to the Lungs IX. The Aerosol Society: Portishead, 2004:210-213.
52. Berridge MS, Heald DL, Muswick GJ, Leisure GP, Voelker KW, Miraldi F. Biodistribution and kinetics of nasal C-11 triamcinolone acetonide. J Nucl Med 1998; 39:1972-1977.
53. Bergstrom M, Cass LMR, Valind S, Westerberg G, Lundberg E-L, Gray S, Bye A, Langstrom B. Deposition and disposition of [11C] zanamivir as an intranasal spray. Clin Pharmacokinet 1999; 36(suppl 1):33-39.
54. Matsune S, Furuta S, Ohyama M, Sato T, Noikura T. Effective administration of aerosol particles into paranasal sinuses by conservative technique for treatment of sinusitis. Jibi Innkoh-ka Ten-Boh 1997; 40:201-205.
55. Newman SP, Simpson M, Fisher A, Iqbal K. Quantification of lung deposition and nasal mucociliary clearance for a nasally administered drug formulation containing chitosan. In: Respiratory Drug Delivery IX. Dalby RN, Byron PR, Peart J, Suman JD, Farr SJ, eds. River Grove: Davis Healthcare International, 2004:617-620.
56. Suman JD, Laube BL, Dalby RN. Comparison of nasal deposition and clearance by aerosol generated by a nebulizer and an aqueous spray pump. Pharm Res 1999; 16:1648-1652.
57. Suman JD, Laube BL, Ta-chun L, Brouet G, Dalby R. Validity of in vitro tests on aqueous spray pumps as surrogates for nasal deposition. Pharm Res 2002; 19:1-6.
58. Clark AR, Borgström L. In vitro testing of pharmaceutical aerosols and predicting lung deposition from in vitro measurements. In: Drug Delivery to the Lung. Bisgaard H, O'Callaghan C, Smaldone GC, eds. New York: Marcel Dekker, 2002:105-142.
59. Thiel CG. Can in vitro particle size measurements be used to predict pulmonary deposition of aerosol from inhalers. J Aerosol Med 1998; 11:S43-S51.
60. Finlay W, Stapleton K, Zuberbuhler P. Variations in predicted regional lung deposition of salbutamol sulphate between 19 nebulizer types. J Aerosol Med 1998; 11:65-80.
61. Price A, Rowland M, Aarons L, Pritchard J, Falcoz C. The use of LUDEP, as a tool, in the prediction of total and regional lung deposition: advantages, limitations and possible developments of the package. In: Drug Delivery to the Lungs IX. Portishead: The Aerosol Society, 1998:51-55.